ATE247471T1 - Cisplatin und topotecan enthaltende zusammensetzung als antitumor. - Google Patents

Cisplatin und topotecan enthaltende zusammensetzung als antitumor.

Info

Publication number
ATE247471T1
ATE247471T1 AT92925253T AT92925253T ATE247471T1 AT E247471 T1 ATE247471 T1 AT E247471T1 AT 92925253 T AT92925253 T AT 92925253T AT 92925253 T AT92925253 T AT 92925253T AT E247471 T1 ATE247471 T1 AT E247471T1
Authority
AT
Austria
Prior art keywords
human
compound
topotecan
antitumor
composition containing
Prior art date
Application number
AT92925253T
Other languages
English (en)
Inventor
Randall Keith Johnson
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE247471T1 publication Critical patent/ATE247471T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Seasonings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT92925253T 1991-11-15 1992-11-13 Cisplatin und topotecan enthaltende zusammensetzung als antitumor. ATE247471T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79304191A 1991-11-15 1991-11-15
PCT/US1992/009864 WO1993009782A1 (en) 1991-11-15 1992-11-13 Combination chemotherapy

Publications (1)

Publication Number Publication Date
ATE247471T1 true ATE247471T1 (de) 2003-09-15

Family

ID=25158913

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92925253T ATE247471T1 (de) 1991-11-15 1992-11-13 Cisplatin und topotecan enthaltende zusammensetzung als antitumor.

Country Status (14)

Country Link
US (1) US5633016A (de)
EP (3) EP0612248B1 (de)
JP (1) JPH07501079A (de)
AT (1) ATE247471T1 (de)
AU (1) AU671605B2 (de)
CA (1) CA2123321C (de)
DE (1) DE69233169T2 (de)
DK (1) DK0612248T3 (de)
ES (1) ES2204894T3 (de)
MX (1) MX9206577A (de)
NZ (1) NZ245112A (de)
PT (1) PT101061B (de)
WO (1) WO1993009782A1 (de)
ZA (1) ZA928771B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552154A (en) 1989-11-06 1996-09-03 The Stehlin Foundation For Cancer Research Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
ZA928771B (en) * 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy
ATE388706T1 (de) * 1993-01-15 2008-03-15 Stehlin Foundation For Cancer Die verwendung von wasserunlöslichem s- camptothecin mit geschlossenem lactonring für die herstellung eines medikamentes zur behandlung von darmkrebs
EP0715854B1 (de) 1994-11-11 2003-09-10 Debiopharm S.A. Karzinostatische Zusammensetzungen, welche Cis-Oxaliplatin und eine oder mehrere andere verträgliche Karzinostatika enthalten
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
WO1997001344A2 (en) * 1995-06-27 1997-01-16 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
GB9804013D0 (en) 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
EP1165144A2 (de) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Mit einem eigengen-wildtyp transduzierte dendritische zellen lösen starke antitumor immunantwort aus
EP1754488A1 (de) 1999-05-24 2007-02-21 Introgen Therapeutics, Inc. Verfahren und Zusammensetzungen für nichtvirale Gentherapie zur Behandlung von hyperproliferativen Krankheiten
JP4776843B2 (ja) 1999-10-01 2011-09-21 イムノゲン インコーポレーティッド 免疫複合体及び化学療法剤を用いる癌治療用組成物及び方法
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
WO2001066144A2 (en) * 2000-03-08 2001-09-13 Rhode Island Hospital, A Lifespan Partner Antineoplastic combination comprising an inhibitor of angiogenesis and an inhibitor of dna topoisomerase i enzyme activity
US6545010B2 (en) * 2000-03-17 2003-04-08 Aventis Pharma S.A. Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
US10293056B1 (en) 2000-05-24 2019-05-21 Board Of Regents, The University Of Texas System Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseases
DE10032256C2 (de) * 2000-07-03 2003-06-05 Infineon Technologies Ag Chip-ID-Register-Anordnung
AU2002220257A1 (en) * 2000-12-07 2002-06-18 Board Of Regents, The University Of Texas System Methods of treatment involving human mda-7
US6476068B1 (en) 2001-12-06 2002-11-05 Pharmacia Italia, S.P.A. Platinum derivative pharmaceutical formulations
US20040009939A1 (en) * 2002-03-05 2004-01-15 Board Of Regent, The University Of Texas System Methods of enhancing immune induction involving MDA-7
WO2004014314A2 (en) 2002-08-12 2004-02-19 David Kirn Methods and compositions concerning poxviruses and cancer
EP1603943A2 (de) * 2003-03-03 2005-12-14 Board of Regents, The University of Texas System Verfahren und zusammensetzungen mit mda-7
US8034790B2 (en) * 2003-12-01 2011-10-11 Introgen Therapeutics Use of MDA-7 to inhibit pathogenic infectious organisms
US20070281041A1 (en) * 2004-03-02 2007-12-06 Introgen Therapeutics, Inc. Compositions and Methods Involving MDA-7 for the Treatment of Cancer
EP1863516A2 (de) * 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Zusammensetzungen und verfahren mit mda-7 zur behandlung von krebs
WO2006124700A2 (en) * 2005-05-12 2006-11-23 Introgen Therapeutics, Inc. P53 vaccines for the treatment of cancers
WO2007006019A1 (en) * 2005-07-06 2007-01-11 University Of South Florida Materials and methods for screening, diagnosis and prognosis of conditions associated with stat protein expression
US8980246B2 (en) 2005-09-07 2015-03-17 Sillajen Biotherapeutics, Inc. Oncolytic vaccinia virus cancer therapy
EP1933857A2 (de) * 2005-09-07 2008-06-25 Jennerex Biotherapeutics ULC Systemische behandlung von metastasierten und/oder systemisch dissemierten tumoren mit gm-csf-exprimierenden pockenviren
WO2007092944A2 (en) * 2006-02-08 2007-08-16 Introgen Therapeutics, Inc. Compositions and methods involving gene therapy and proteasome modulation
US20110028536A1 (en) * 2006-08-18 2011-02-03 Gjerset Ruth A Methods and compositions for topoisomerase i modulated tumor suppression
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
KR20080084528A (ko) 2007-03-15 2008-09-19 제네렉스 바이오테라퓨틱스 인크. 종양살상형 백시니아 바이러스 암 치료
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200920347A (en) * 2007-07-16 2009-05-16 Poniard Pharmaceuticals Inc Oral formulations for picoplatin
AU2009210654A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and bevacizumab to treat colorectal cancer
KR101838472B1 (ko) 2009-09-14 2018-03-15 신라젠(주) 종양 용해 백시니아 바이러스 병용 암 치료요법
EP3327148B1 (de) 2010-06-18 2021-03-17 Myriad Genetics, Inc. Verfahren zur vorherbestimmung des status der gene brca1 und brca2 in einer krebszelle
ES2704303T3 (es) 2010-08-24 2019-03-15 Dana Farber Cancer Inst Inc Procedimientos para la predicción de una respuesta contra el cáncer
US9919047B2 (en) 2011-01-04 2018-03-20 Sillajen, Inc. Generation of antibodies to tumor antigens and generation of tumor specific complement dependent cytotoxicity by administration of oncolytic vaccinia virus
ES2768344T3 (es) 2011-06-17 2020-06-22 Myriad Genetics Inc Métodos y materiales para evaluar el desequilibrio alélico
JP6325453B2 (ja) 2011-12-21 2018-05-16 ミリアド・ジェネティックス・インコーポレイテッド ヘテロ接合性の消失（ｌｏｓｓｏｆｈｅｔｅｒｏｚｙｇｏｓｉｔｙ）を評価するための方法および材料
WO2013094581A1 (ja) * 2011-12-21 2013-06-27 株式会社ヤクルト本社 新規なカンプトテシン誘導体
ES2687024T3 (es) 2012-02-23 2018-10-23 Children's Medical Center Corporation Procedimientos para predecir la respuesta contra el cáncer
CA2867434C (en) 2012-06-07 2021-10-12 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
DK2981624T3 (da) 2013-04-05 2020-03-02 Myriad Genetics Inc Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling
EP3073825A4 (de) * 2013-11-25 2017-06-21 The University of Toledo Inhibitoren von ercc1-xpf und verfahren zur verwendung davon
CA2931181C (en) 2013-12-09 2023-01-24 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
DK3686288T3 (da) 2014-08-15 2023-05-22 Myriad Genetics Inc Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens
EP4141127B1 (de) 2021-08-30 2024-10-09 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Verfahren zur bewertung des mangels an homologer rekombination in eierstockkrebszellen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342776A (en) 1979-11-05 1982-08-03 Merck & Co., Inc. 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic acid oxidase
US4399276A (en) 1981-01-09 1983-08-16 Kabushiki Kaisha Yakult Honsha 7-Substituted camptothecin derivatives
US4473692A (en) 1981-09-04 1984-09-25 Kabushiki Kaisha Yakult Honsha Camptothecin derivatives and process for preparing same
JPS5839685A (ja) 1981-09-04 1983-03-08 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体及びその製造法
JPS58154582A (ja) 1982-03-10 1983-09-14 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体およびその製造法
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
US5004758A (en) 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
ES2165346T3 (es) 1989-09-15 2002-03-16 Res Triangle Inst Analogos de 10,11-metilendioxi-20(rs)-camptotecina y 10,11-metilendioxi-20(s)-camptotecina.
ZA928771B (en) * 1991-11-15 1993-09-08 Smithkline Beecham Corp Combination chemotherapy

Also Published As

Publication number Publication date
HK1012268A1 (en) 1999-07-30
PT101061A (pt) 1994-06-30
EP1393729A2 (de) 2004-03-03
PT101061B (pt) 1999-07-30
DE69233169D1 (de) 2003-09-25
EP1393730A3 (de) 2004-03-17
JPH07501079A (ja) 1995-02-02
CA2123321A1 (en) 1993-05-27
EP1393729A3 (de) 2004-03-17
DE69233169T2 (de) 2004-05-27
WO1993009782A1 (en) 1993-05-27
EP0612248B1 (de) 2003-08-20
EP0612248A1 (de) 1994-08-31
EP1393730A2 (de) 2004-03-03
NZ245112A (en) 1995-07-26
ES2204894T3 (es) 2004-05-01
DK0612248T3 (da) 2003-12-08
MX9206577A (es) 1993-05-01
AU671605B2 (en) 1996-09-05
EP0612248A4 (en) 1996-05-08
CA2123321C (en) 2003-09-30
ZA928771B (en) 1993-09-08
AU3137993A (en) 1993-06-15
US5633016A (en) 1997-05-27

Similar Documents

Publication Publication Date Title
DE69233169D1 (de) Cisplatin und Topotecan enthaltende Zusammensetzung als antitumor.
DE69425661D1 (de) IMIDAZO [4,5-c]PYRIDIN-4-AMINE
IL104006A (en) Azaheterocyclylmethyl-chromans their preparation and pharmaceutical compositions containing them
IL89840A0 (en) Substituted flavonoid compounds and salts thereof,their preparation and pharmaceutical compositions containing them
EP0275005A3 (en) Complex compounds of bioflavonoids with phospholipids, their preparation and use, and pharmaceutical and cosmetic compositions containing them
EP0430045A3 (en) Ascorbic acid tocopheryl phosphate diesters for inhibition of maillard's reaction
GR3006177T3 (de)
EP0344880A3 (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer
AU564439B2 (en) Pharmaceutical compositions containing l-alpha- glycerylphosphorylcholine
IL91047A0 (en) Pharmaceutical compositions containing a zinc complex
GR3033253T3 (en) Tri(platinum) complexes
DE3474774D1 (en) Therapeutic compositions for oral use containing stable s-adenosy1-l-methionine salts
AU4042795A (en) Treatment of non-small cell lung carcinoma
ATE476182T1 (de) Pharmazeutische zusammensetzung zur verwendung in der behandlung von eierstockkrebs
IL106289A0 (en) Phospholipid derivatives, their preparation and pharmaceutical compositions containing them
ATE87314T1 (de) Platin-arzneimittel.
MY105876A (en) Pharmaceutical compositions with anti-cancer activity and method for the treatment of cancer.
ATE227573T1 (de) Orale oder intramuskuläre behandlung von pankreaskrebs durch wasserunlösliches s- camptothecin mit geschlossenem lactonring

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0612248

Country of ref document: EP

REN Ceased due to non-payment of the annual fee